Agilent Expands FDA-Approved PD-L1 Testing for KEYTRUDA Across Four Cancer Types
SANTA CLARA, Calif., June 2, 2026 Agilent Technologies announced that the U.S. Food and Drug Administration (FDA) has approved...
Pembrolizumab
Advertisement
Anaveon Reports Promising Phase 1 ANV600 Cancer Data at ASCO 2026
BASEL, Switzerland — May 28, 2026 Anaveon announced new clinical data from its Phase 1 EXPAND-1 trial showing encouraging...
Virax Biolabs Reports Positive Long COVID Data
LONDON, United Kingdom, May 26, 2026 Virax Biolabs Group Limited has announced encouraging early clinical data for ViraxImmune™, its...
Citius Oncology LYMPHIR ASCO Phase 1 Data
CRANFORD, New Jersey, May 26, 2026 Citius Oncology, Inc. has announced that new Phase 1 clinical study data evaluating...
Adcendo and MSD Expand KEYTRUDA Cancer Trial
COPENHAGEN, Denmark, May 26, 2026 Adcendo ApS has announced a new clinical collaboration and supply agreement with MSD (Merck...
Advertisements
Merck’s KEYTRUDA and Padcev Combination Shows Strong Survival Benefit Ahead of EU Approval
RAHWAY, New Jersey, May 24, 2026 Merck announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
OSE Immunotherapeutics Reports Positive TEDOVA Data
NANTES, France, May 22, 2026 OSE Immunotherapeutics announced positive topline results from the Phase 2 TEDOVA trial evaluating Tedopi®...
Astellas’ PADCEV Combo Wins CHMP Support in MIBC
Tokyo, Japan – May 22, 2026 Astellas Pharma Inc. announced that the European Medicines Agency’s Committee for Medicinal Products...
Mestag Therapeutics Doses First Patient in STARLYS Trial of MST-0312 for Solid Tumors
CAMBRIDGE, UK, May 19, 2026 Mestag Therapeutics announced the first patient has been dosed in the Phase 1 STARLYS...
BioInvent Reports Strong BI-1808 CTCL Responses at EHA
LUND, Sweden – May 12, 2026 BioInvent International AB announced new Phase 2a clinical data demonstrating that its investigational...
Advertisement
